Immunome, Inc. (IMNM) vs Zai Lab Limited Unsponsored ADR (ZLAB)
Immunome, Inc. and Zai Lab Limited Unsponsored ADR are both Biotechnology companies. Zai Lab Limited Unsponsored ADR is the larger, with a market value of $2.9B against $2.6B — 1.1× the size. Immunome, Inc. grew revenue faster over the last twelve months: 16.7% against 5.10%. Immunome, Inc. has the higher net margin (0.00% vs −41.9%) and the lower return on invested capital (−3,323.0% vs −129.3%). Across the 17 metrics below, Immunome, Inc. leads on 9 and Zai Lab Limited Unsponsored ADR on 8.
Valuation
Profitability
| Metric | IMNM | ZLAB | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 56.47% | 65.16% |
| Operating margin | 0.00% | (58.74%) | 0.00% |
| Net margin | 0.00% | (41.86%) | 0.00% |
| Free cash flow margin | 0.00% | (36.13%) | 0.00% |
| Return on equity | (64.03%) | (26.91%) | (57.72%) |
| Return on assets | (59.03%) | (16.81%) | (49.22%) |
| Return on invested capital | (3,322.99%) | (129.34%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack